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Osteogenesis imperfecta (OI) is a heritable disorder due to mutations in type 
I collagen.  Normal type I collagen forms a heterotrimeric protein comprised 
of two proα1(I) chains and one proα2(I) chain [α1(I)2α2(I)].  The osteogenesis 
imperfecta murine (oim) model mouse contains a single nucleotide deletion in 
the proα2(I) gene (COL1A2) resulting in non-functional proα2(I) chains and 
production of  homotrimeric type I collagen containing three proα1(I) 
collagen chains, [α1(I)3], resulting in small body size, increased bone 
fragility and altered bone mineralization. 
 
The overall goal of this study is to correct the oim defect by introducing 
normal COL1A2 genes into oim cells.  Oim dermal fibroblasts were transfected 
with a series of COL1A2 gene constructs containing the full-length murine 
proα2(I) collagen cDNA driven by various lengths of  the murine COL1A2 
promoter (1.5kb, 3.0kb, and 6.0kb) along with a COL1A2 enhancer.  These DNA 
constructs were cotransfected with pcDNA3 containing a neomycin resistance 
gene, which allows for selection of stably transfected cell lines.  Various 
assays have been developed to monitor proa2(I) collagen expression at the 
DNA, RNA and protein levels.  A PCR assay was used to confirm genomic 
incorporation of transgenic COL1A2 gene constructs and an RT-PCR assay used 
to confirm expression of normal proα2(I) collagen mRNA.  Denaturing urea-SDS 
polyacrylamide gel electrophoresis along with Western blotting analyses using 
anti-murine α1(I) and α2(I) collagen antibodies were used to confirm normal 
proα2(I) collagen expression at the protein level as well as its 
incorporation into normal heterotrimeric type I collagen.   
 
All the necessary tools have been established for evaluating the efficacy of 
transfection.  Currently, the first series of stably transfected oim cell 
lines are being expanded for analyses as described above.  Although this 
study is aimed at ‘fixing’ the oim mutation via gene therapy, valuable data 
will also be collected regarding the effectiveness of the variable length 
promoter regions in enhancing the expression of the normal COL1A2 gene. 
